# This guide gives you the facts needed for a visit *About This Joint Guide — Stem Cell Clinic Phoenix* > How this stem cell clinic Phoenix guide explains aching, urgent signs, and ways to prepare for a useful office visit. ## Phoenix has many places offering joint care Phoenix gives you many places to ask about a sore joint. This guide covers common causes, home care, urgent signs, and visit questions. It can't tell which cause fits you because that takes an exam. Use it to prepare, then rely on your own exam. ## Your doctor checks what this guide cannot This report is published by the owners of the QC Kinetix clinics serving the Phoenix area. If a reader books after using these pages, that business can benefit. That ownership matters when you consider any clinic information. The health information here is general. Your doctor feels the joint, tests its movement, and reads an X-ray beside your symptoms. The doctor also reviews past health problems and every medicine you take before suggesting another medicine. A page can't do those things. Prepare by writing where the soreness sits and how it began. Add what worsens it, what eases it, and which daily task is hard. Take those notes, any X-ray report, and your medicines to the visit. This helps the doctor focus on the trouble you feel. Some symptoms need faster care. A fever while the joint is hot or swollen calls for prompt help. A major injury, sudden weakness, or a bent-looking joint also needs quick attention. Get emergency help if back pain begins with loss of bladder or bowel control. For ordinary soreness, gentle movement, pacing, a brace, or physical therapy may help. Ask how long to try each step and what change to watch. If soreness keeps limiting your day, arrange an exam. The exam gives advice based on your joint and health. ## Sources 1. The International Society for Cell & Gene Therapy position statement holds that the acronym MSC should mean mesenchymal STROMAL cells and should only be called stem cells where rigorous in vitro and in vivo evidence of stemness exists for that specific preparation. Viswanathan S, et al. — [Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature](https://pubmed.ncbi.nlm.nih.gov/31526643/). *Cytotherapy*, 2019. DOI: 10.1016/j.jcyt.2019.08.002. 2. The 2018 AAOS/NIH consensus work group recommended that minimally manipulated mixed cell preparations be called CELL THERAPY rather than stem cell therapy, and that their untested and uncharacterised nature be clearly communicated to patients and the public, because stem cells have properties these preparations do not meet. Chu CR, et al. — [Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference](https://pubmed.ncbi.nlm.nih.gov/30300216/). *J Am Acad Orthop Surg*, 2019. DOI: 10.5435/JAAOS-D-18-00305. 3. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added. Bannuru RR, et al. — [OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis](https://pubmed.ncbi.nlm.nih.gov/31278997/). *Osteoarthritis Cartilage*, 2019. DOI: 10.1016/j.joca.2019.06.011. 4. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months. Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nat Med*, 2023. DOI: 10.1038/s41591-023-02632-w. 5. A 2025 systematic review and meta-analysis of 8 randomized trials in 502 patients found intra-articular mesenchymal stem cells improved WOMAC scores versus control at 6 months (MD 7.44, 95% CI 1.45-13.42) and 12 months (MD 10.31, 95% CI 0.96-19.67), with wide confidence intervals and a small pooled sample. Cao M, et al. — [Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/40055739/). *Stem Cell Res Ther*, 2025. DOI: 10.1186/s13287-025-04252-2. 6. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable. Previtali D, et al. — [Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression](https://pubmed.ncbi.nlm.nih.gov/41031623/). *EFORT Open Rev*, 2025. DOI: 10.1530/EOR-2025-0022. 7. 21 CFR 1271.10(a) sets the four criteria a human cell or tissue product must meet to be regulated SOLELY under section 361 of the Public Health Service Act: it must be minimally manipulated; intended for homologous use only, as reflected by labeling and advertising; not combined with another article beyond water, crystalloids or a preserving agent; and either have no systemic effect and not depend on the metabolic activity of living cells, or else be for autologous use, use in a close blood relative, or reproductive use. US Code of Federal Regulations, Title 21 — [21 CFR 1271.10 - Are my HCT/P's regulated solely under section 361 of the PHS Act](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-A/section-1271.10). *null*, 2004. 8. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain. US Food and Drug Administration, Center for Biologics Evaluation and Research — [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes). *null*, 2020. ## An exam can help when soreness stays When home care hasn't helped enough, QC Kinetix can review your joint. Care comes from medical providers, meaning the clinicians who check the joint and discuss non-surgical choices. Write down every medicine, take your X-ray report, and note difficult daily tasks. For the west-Phoenix location, use 9305 W. Thomas Rd., Suite 460, Phoenix, AZ 85037, or call (602) 837-PAIN. Book a free consultation: --- Understand the soreness. Know your choices. Plain guidance for a sore Phoenix joint, helpful home care, office visits, and non-surgical choices when aching stays. Plain facts about sore joints and ways to prepare for an office visit. This site is operated by the owners of the QC Kinetix Phoenix-area clinics, including the Banner Estrella, Scottsdale, Peoria, and Chandler locations, and the business can benefit when a reader books. © 2026 Phoenix Trial Ledger. General health education, not medical advice or a diagnosis for your joint.